Fistula First Breakthrough Initiative (FFBI): Lessons About Arteriovenous Fistula Prevalence Goals  Andrew D. Howard, MD, Robin S. Howard, MA, Stuart L. Goldstein, MD, Klemens B. Meyer, MD  American Journal of Kidney Diseases  Volume 61, Issue 3, Pages 523-525 (March 2013) DOI: 10.1053/j.ajkd.2012.09.014 Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Annual changes in prevalent AVF rates for all networks 2004-2009 plotted against their annualized prevalent rate in the prior year. Each point represents actual March-to-March change, with the solid and dashed lines representing the model prediction (goal estimated from regression model of past performance) and 95% confidence intervals, respectively. American Journal of Kidney Diseases 2013 61, 523-525DOI: (10.1053/j.ajkd.2012.09.014) Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Annual changes in (A) 2010 and (B) 2011 for prevalent AVF rates of all networks relative to their actual previous March rate. Solid line, model prediction (goal estimated from regression model of past performance); broken line, CMS target goal; filled circles, networks with actual changes closer to the rate predicted by the nonlinear model (model prediction more accurate); open circles, networks with actual changes closer to the CMS formula. American Journal of Kidney Diseases 2013 61, 523-525DOI: (10.1053/j.ajkd.2012.09.014) Copyright © 2013 National Kidney Foundation, Inc. Terms and Conditions